Fig. 4

Cells expressing elevated levels of MYC are sensitive to inhibition of the WNT pathway. a Diagram of WNT pathway inhibitors, their structures, and targets. b 5000 DLD1, RKO, and HCT116 were plated separately in each well of 12-well plates and incubated with DMSO or ICG-001 in triplicate for 6 days. Cells were then stained with crystal violet, and the relative viabilities were qualified with ImageJ. c DLD1 cells were co-transfected with either control or MYC siRNA with a TOPFlash or FOPFlash luciferase reporter and treated with either DMSO or 20 μM ICG-001 overnight, and then luciferase activity was measured. d DLD1 cells with or without MYC overexpression were transfected with TOPFlash or FOPFlash luciferase reporter and treated with either DMSO or 20 μM ICG-001 overnight, then luciferase activity was measured. e 20,000 Rat1 myc −/− control fibroblast cells or Rat1 myc −/− cells reconstituted with human MYC were plated in 12-well plates and incubated with the indicated inhibitors in triplicate for 6 days. Cells were then stained with crystal violet, and the relative viabilities were qualified with ImageJ. f 5000 ARPE-19 cells with or without MYC overexpression were plated in 12-well plates and incubated with the indicated inhibitors in triplicate for 7 days. Cells were then stained with crystal violet, and the relative viabilities were qualified with ImageJ. g 5000 ARPE-19 cells with or without MYC overexpression were plated in 12-well plates and incubated with 20 μM ICG-001 in triplicate for 1–7 days. Cells were then stained with crystal violet, and the relative viabilities were qualified with ImageJ and all samples are normalized to 0-day sample of each cell line. * p < 0.05, ** p < 0.01, *** p < 0.001, ns not significant